Related Experiment Video
Updated: Sep 10, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Fifteen-year longitudinal population-based study of very late-diagnosed multiple sclerosis: Epidemiological and
Claudio Solaro1, Novella Pretti2, Michele Messmer Uccelli3
1Neurology Unit, Galliera Hospital, Genoa, Italy; Scientific Research Area, Italian Multiple Sclerosis Foundation (FISM), Genoa, Italy.
Background:
The epidemiology of Multiple Sclerosis (MS) is evolving with increasing incidence and prevalence in older individuals, but data on very late-onset MS (VLOMS, ≥60 years) remains limited.
Objective:
This study evaluates clinical features, disease progression, and long-term disability accumulation in VLOMS subjects from the Genoa MS cohort.
Methods:
Among 530 incident MS cases (1998-2007), 38 (7.2 %) were diagnosed at ≥60 years. Data were collected and analyzed over a 15-year follow-up.
Results:
At diagnosis, the mean age was 65 years, with 22 females (57.9 %). 24 (63 %) had primary progressive MS (mean EDSS 3.8), and 14 (37 %) had relapsing-remitting MS (mean EDSS 3.0). Of the latter, 11 (79 %) converted to secondary progressive MS within a mean of 3.7 years. Overall, 35 (92 %) subjects reached EDSS 6 within a mean of 6.3 years. Number of comorbidities at diagnosis strongly related to the probability of being alive at last follow-up. 16 subjects received DMT, and only three remained on treatment at last follow-up. Mortality was 32 %, with a mean survival of 10 years from diagnosis.
Conclusions:
VLOMS presents a severe disease course with rapid disability accumulation. Age at diagnosis remains the strongest predictor of disease progression, highlighting the need for tailored management strategies.
Related Concept Videos
Longitudinal Research
Longitudinal Studies
Introduction to Epidemiology
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

